Two MEK inhibitors were tested against recurrent low-grade serous carcinomas of the ovaries, fallopian tubes, or peritoneum, but only one offered clinical benefit over standard care, say researchers.
Medscape Medical News …read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
